| Name | Title | Contact Details |
|---|---|---|
Kim Raineri |
Chief Manufacturing and Technology Officer | Profile |
Kim Raineri |
Chief Manufacturing and Technical Operations Officer | Profile |
Endobiologics is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Canadian Bacterial Diseases Network (CBDN) is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NexBio, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Welcome to the new era of skin cancer detection. At DermTech we bring precision to the practice of dermatology through non-invasive genomic testing. And we developed the Smart Sticker that`s making it possible. The DermTech Smart Sticker collects an RNA sample by painlessly lifting skin cells off the entire surface of a mole. This gives doctors the power to diagnose skin cancer in its earliest stages—without a scalpel, without cutting, without scarring. After collection, stickers are sent to our team of scientists in the Gene Lab, the only commercial lab to extract nucleic acids and other proteins from non-invasive skin samples. We amplify RNA molecules to detect two specific genes that are highly predictive of melanoma—PRAME and LINC00518. This process provides 10,000x greater precision in the ability to detect melanoma. We have created the step before the scalpel—a tool doctors have never had before. Now the doctor has the choice of using a non-invasive, highly accurate test to check for melanoma without cutting. And this is just the beginning. We are developing other tests using the Smart Sticker that will further advance early disease detection.
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.